Galmed Pharma (GLMD) Tops Q1 EPS by 10c

Galmed Pharma (NASDAQ: GLMD) reported Q1 EPS of ($0.15), $0.10 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
• ’Not your father’s Sandisk’: Rosenblatt starts coverage at Buy